Drug duo aims to tackle tough lung cancers after first treatment fails
NCT ID NCT07703228
First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time
Summary
This trial tests whether combining sacituzumab tirumotecan (a targeted antibody-drug conjugate) with anlotinib (a multi-targeted pill) can shrink tumors or slow cancer growth in people with advanced non-squamous non-small cell lung cancer that has no known driver gene mutations. Participants receive both drugs after their first-line immunotherapy and chemotherapy stopped working. The study also looks for biomarkers in blood that might predict who benefits most.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- a combination of sacituzumab tirumotecan (an antibody-drug conjugate targeting TROP2) and anlotinib (a multi-target tyrosine kinase inhibitor)
- What this could lead to
- If successful, this combination could offer a new second-line treatment option for people with advanced non-squamous lung cancer who have no targetable gene mutations.
- What could go wrong
- This is a small, early-phase single-arm study without a control group, so results may not be definitive. Side effects from the drug combination could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTASES are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Nanfang Hospital of Southern Medical University
Guangzhou, Guangdong, 510515, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new Antibody-Drug conjugate outsmart advanced lung cancer?
- Experimental pill SHY-ONC6 takes on Hard-to-Treat cancers
- Blood test may let cancer patients take safe breaks from immunotherapy
- New combo aims to stall lung cancer when targeted pills start to fail
- New hope for lung cancer patients: drug combo targets tough tumors
- New hope for lung cancer: experimental drug combo enters trial